AI Article Synopsis
- Combigan is an eye drop solution that combines two drugs—brimonidine and timolol—used to lower eye pressure in patients with glaucoma or high eye pressure.
- Recently, there have been reports of using Combigan topically to treat superficial infantile hemangiomas, which are benign tumors in infants.
- A case is discussed where a 2-month-old girl experienced severe toxicity from brimonidine after applying Combigan to her hemangioma, leading to life-threatening side effects that required emergency medical intervention.
Article Abstract
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α-2 adrenergic agonist, with 0.5% timolol, a nonselective β-adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2-month-old girl who developed life-threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.12868 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ex Vivo Irritation Evaluation of a Novel Brimonidine Nanoemulsion Using the Hen's Egg Test on Chorioallantoic Membrane (HET-CAM).
Cureus
August 2024
Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, IRQ.
Introduction: The hen's egg test on chorioallantoic membrane (HET-CAM) assay is a cost-effective and well-validated, non-animal-based method for evaluating the irritant potential and eye toxicity of substances. A colloidal dispersion of a surfactant and a cosurfactant with a nanosize range is called a nanoemulsion (NE), which is formed by mixing immiscible liquids and stabilized by surfactants. Patients with glaucoma are commonly prescribed Brimonidine (BR), an alpha-2 adrenergic agonist, to lower their intraocular pressure.
View Article and Find Full Text PDFAre Alpha-2 Adrenergic Agonists Being Used in Infants?
J Ocul Pharmacol Ther
August 2024
Department of Ophthalmology, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
To identify and quantify adverse events (AEs) associated with alpha-2 adrenergic agonists prescribed for the treatment of glaucoma in infants. We queried the Federal Adverse Event Reporting System (FAERS) from 2004-2023Q1 for AE reports related to brimonidine use in patients aged 12 months or younger. We then conducted a disproportionality analysis using data mining algorithms, including the reporting odds ratio, proportional reporting ratio, empirical bayes geometric mean, and information component to identify significant symptoms.
View Article and Find Full Text PDFSustained release of brimonidine from conjunctival sac insert to reduce intraocular pressure for glaucoma treatment.
Expert Opin Drug Deliv
June 2024
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Shanghai Medical College, Fudan University; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences; Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China.
Background: Glaucoma is one of the major irreversible blinding eye diseases in the world. Reducing intraocular pressure (IOP) is the primary treatment option, and taking eye drops daily is the common method. However, short drug duration and poor bioavailability of eye drops may lead to unsatisfied therapeutic effects and inadequate patient compliance.
View Article and Find Full Text PDFBrimonidine Eye Drops within the Reach of Children: A Possible Foe.
Children (Basel)
March 2024
Department of Pediatrics, Santo Spirito Hospital, Azienda Sanitaria Pescara, 65121 Pescara, Italy.
Brimonidine, a selective alpha-2 adrenergic agonist used for the treatment of open-angle glaucoma, has been shown to cause neurological side effects such as unresponsiveness, lethargy, hypoventilation, and stupor, mimicking opioid toxicity. We report one case of transient encephalopathy in a toddler, in whom accidental brimonidine toxicity was suspected and then confirmed by a toxicology study. The healthy 8-month-old girl was taken to the pediatric ER since she was drowsy and hypotonic with miosis.
View Article and Find Full Text PDFControlling the Adsorption and Release of Ocular Drugs in Metal-Organic Frameworks: Effect of Polar Functional Groups.
Inorg Chem
November 2022
Laboratorio de Materiales Avanzados, Departamento de Química Inorgánica-Instituto Universitario de Materiales, Universidad de Alicante, E-03690 San Vicente del Raspeig, Spain.
A series of UiO-66 materials with different functional groups (-H, -NH, and -NO) have been evaluated for the adsorption and release of a common ocular drug such as brimonidine tartrate. UiO-66 samples were synthesized under solvothermal conditions and activated by solvent exchange with ethanol. Experimental results suggest that the incorporation of surface functionalities gives rise to the development of structural defects (missing linker defects) but without altering the basic topology of the UiO-66 framework.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!